Stanley Lab: Information about using brains

Information for

Applicants For Using Postmortem Brain Tissue From the Stanley

Foundation Neuropathology Consortium


sides of the brain are fixed in 105 phosphate buffered formalin

or frozen at -70°C, except for the brainstem and cerebellum,

which are completely frozen. The formalin fixed blocks are

embedded in paraffin. The frozen half is initially coronally

sectioned into 8-10 slices, then rapidly frozen in a slurry of

isopentane and dry ice. Regions of great interest are being

completely sectioned into 14 micron (frozen) or 10 micron (fixed)

sections. Except for these regions, small 0.5 to 1.0 gm. blocks

are available for research. Regions completely sectioned to date

are the hippocampus-amygdala, anterior striatum, and prefontal

cortex. Other areas to be completely sectioned are the anterior

cingulate, part of the brainstem, and part of the



wishing to obtain these brains should fill out the required

application. Brain tissue will be allocated on the basis of

tissue availability, quantity requested, and relative importance

of the proposed project.


must agree to the following conditions for participation:

  1. Researcher

    will test all 60 brains.

  2. Brains

    will be sent coded and the code will vary from

    researcher to researcher. Once your study has been

    completed, you will send us the results and we will

    simultaneously send you the code. Whenever possible,

    we would like to receive your results on a disc.

  3. You

    may publish the results of your study wherever you

    wish, acknowledging the Stanley Foundation

    Neuropathology Consortium as the source of the


    Acknowledgement at the end of any such publication

    should read:

    “Postmortem brains were

    donated by the Stanley Foundation Brain

    Consortium courtesy of Drs. Llewellyn B. Bigelow,

    Juraj Cervenak, Mary M. Herman, Thomas M. Hyde,

    Joel E. Kleinman, José D. Paltàn, Robert M.

    Post, E. Fuller Torrey, Maree J. Webster, and

    Robert H. Yolken.

  4. You

    may not share the samples with other researchers. You

    will notify us if you take the samples with you if

    you move to another institution or if you wish to use

    the samples for research other than that which you

    originally proposed.

  5. If

    more than one researcher wishes to do the same

    measurement (e.g., D4 receptors, interleukins), we

    will notify both parties involved that the other(s)

    are also doing that measurement. We plan to notify

    all Consortium participants of all ongoing research

    projects by means of a Web page.

  6. If

    any measurements are made after the code has been

    broken on your initial samples, you should note in

    any publication of the work that the work was done

    unblinded. You can apply for re-coded


  7. The

    results we receive from you will become part of a

    Stanley Foundation Neuropathology Consortium data set

    in which results from various studies will be

    correlated. Correlations will be done both by

    anatomical region (e.g. different measurements in the

    anterior hippocampus) as well as by type of

    measurements (e.G., GABA receptors in different

    regions). The results of these correlations and

    comparisons between diagnostic groups will be

    published under the Stanley Foundation Neuropathology

    Consortium with one or two researchers from each

    research site listed at the top of the article.

    Individual authorship at the beginning of the article

    will go to (a) any researcher whose data comprises 20

    percent or more of the data being reported in that

    article and (b) individuals involved in data analysis

    and administration of the Consortium. Final decisions

    regarding authorships will be decided by a Consortium

    Authorship Committee consisting of Drs. Joel

    Kleinman, Fuller Torrey, and Robert Yolken.

In summary, by sharing

the same brains among a broad group of researchers, we hope to

resolve conflicting neuropathological, neurovirological,

neuroimmunological, and neurochemical findings which have been

reported; provide a more definitive description of brain

pathology in schizophrenia, bipolar disorder, and major

depression compared to each other and to normal controls; and to

stimulate further research in this field.

Additional information on

the Consortium can be obtained from Dr. Torrey at:

E. Fuller Torrey,


Stanley Foundation Research Studies

NIMH Neuroscience Center at St. Elizabeths Hospital

2700 Martin Luther King Avenue, SE

Washington DC 20032

202-373-6105/Fax: 202-373-6252

E-mail: <mailto:[email protected]>

Last revised on 05 June 2000.